UCI
& UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Recruiting |
|
|
UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
|
UCI |
|
Pluristem Ltd. |
Critical Limb Ischemia (CLI) |
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor |
Recruiting |
|
|
UCI |
|
ReNeuron Limited |
Stroke |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) |
Recruiting |
|
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
UCI
& UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Recruiting |
|
|
UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
Active, not recruiting |
|
|
UCI |
|
BrainStorm Cell Therapeutics |
Amyotrophic Lateral Sclerosis (ALS) |
A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS |
Recruiting |
|
UCI
& UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
Active, not recruiting |
|
|
UCI |
|
ImmunoCellular Therapeutics |
Cancer - Brain |
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma |
No longer active |
|
|
UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease |
Recruiting |
|
|
UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
|
UCI |
|
Pluristem Ltd. |
Intubated COVID-19 patients |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 |
Recruiting |
|
UCI
& UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Recruiting |
|
|
UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens |
Recruiting |
|
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus |
Recruiting |
|
|
UCSD |
|
UCSD |
Cancer - Leukemia |
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
No longer active |
|
|
UCSD |
|
UCSD |
Cancer - Breast |
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer |
Recruiting |
|
|
UCSD |
|
Mesoblast |
Heart Failure |
The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure |
Recruiting |
|
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
Recruiting |
|
UCSD
& City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Recruiting |
|
|
UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
Recruiting |
|
|
UCSD |
|
Persimmune, Inc. |
Cancer - Blood |
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) |
Recruiting |
|
|
UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
|
UCSD |
|
UCSD |
Cancer - Leukemia |
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 |
No longer active |
|
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
Recruiting |
|
|
UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
|
UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Recruiting |
|
|
UCLA |
Scott Nowicki, MD, PhD |
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
Recruiting |
|
|
UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Recruiting |
|
|
UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
UCLA
& UCI |
|
SanBio |
Brain Injury |
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
Active, not recruiting |
|
|
UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
|
UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
No longer active |
|
|
UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
|
UCLA |
|
UCLA |
Cancer |
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) |
No longer active |
|
|
City of Hope |
|
Angiocrine Bioscience |
Cancer - Leukemia |
A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation |
Recruiting |
|
|
City of Hope |
|
Glaxo Smith Kline (GSK) |
Cancer - Lung |
Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
|
City of Hope |
Elizabeth Budde, MD
626-218-2405 |
Kite Pharma |
Cancer - Lymphoma |
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma |
Recruiting |
|
|
City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Ovarian |
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
Recruiting |
|
|
City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Sickle Cell Disease |
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
|
|
City of Hope |
|
Atara Bio. |
Cancer - Nasopharyngeal Carcinoma |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
Recruiting |
|
|
City of Hope |
|
Sangamo Therapeutics |
Hemophilia B |
Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
Recruiting |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Recruiting |
|
